To The Moon

$VolitionRX Ltd(VNRX)$ VolitionRX Ltd. (NYSE: VNRX) has published a new corporate presentation highlighting its focus on licensing its proprietary epigenetics-based diagnostic technologies targeting cancer and sepsis. The company reports a proven licensing model validated in the veterinary market, with multiple products already launched and a strong intellectual property portfolio consisting of 56 patent families and 71 granted patents with coverage up to 2044. The presentation outlines VolitionRX’s commercialization strategy, which is based on an asset-light business model leveraging commercial partnerships and out-licensing agreements. The approach includes upfront and milestone payments, recurring revenue from sales of key components, and roya

$Momentus Inc.(MNTS)$  FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference. The presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026, at The St. Regis in San Francisco, California.It is both a risk and an opportunity.

$Ventyx Biosciences, Inc.(VTYX)$ FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference. The presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026, at The St. Regis in San Francisco, California.It is both a risk and an opportunity.

$纳斯达克(.IXIC)$  FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference. The presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026, at The St. Regis in San Francisco, California.It is both a risk and an opportunity.

$标普500(.SPX)$  FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference. The presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026, at The St. Regis in San Francisco, California.It is both a risk and an opportunity.

The US government is pushing forward a series of bills related to AI, semiconductors, electric vehicles, batteries, and critical minerals, all essentially aimed at one goal: bringing key resources back to the US and completely eliminating dependence on foreign graphite. Against this backdrop, Westwater Resources has become a target of policy support. Why? Because there are very few companies in the US with the capability to process battery-grade graphite, and the US currently imports over 90% of its graphite. If the US wants to promote AI and electric vehicles, it must first solve the graphite supply problem, and WWR happens to have graphite processing projects and a supply chain layout within the US. This means: 🔹 In the future, all electric vehicle and battery manufacturers seeking gover

$60 degrees pharmaceuticals, Inc.(SXTP)$ It's so quiet. Are people disappointed in you? But I firmly believe you will come. Keep going!

$60 degrees pharmaceuticals, Inc.(SXTP)$ 💎 **Seize the Next Wave of Biotech Boom! SXTP: An Investment Opportunity You Can't Miss!** 60 Degrees Pharmaceuticals (NASDAQ: SXTP) has officially submitted a Breakthrough Therapy Designation request to the FDA for its core drug, Tafenoquine, for **babesiosis**. This is not only a milestone for the company, but also a potential super catalyst to ignite its stock price! 🌱 **Huge Market, Zero Competition!** Babesiosis is a dangerous tick-borne parasitic disease for which there is currently **no specific FDA-approved treatment** in the United States. The company estimates that there are **4,400 to 190,000 unmet medical needs** annually. Independent research indicates that the U.S. babesiosis market has a **p

$Citius Pharmaceuticals, Inc.(CTXR)$  🔥 **Revolutionary Therapy, Addressing Unresolved Medical Pain: Citius is Rewriting the Rules of Patient Survival** > **"When 82% of refractory infections subside within 72 hours, when end-stage hepatitis patients regain liver vitality—this is not the future, but Citius's clinical answer today."** #### ✅ **Clinical Provenance of Core Products, Data is Truth:** 1. **Mino-Lok® (Ultimate Solution for Catheter Infections)** → **82% Global Phase III Clinical Cure Rate**, crushing standard therapies (*p<0.001*) → **Rapid Clearance of Biofilm within 72 Hours**, buying back life for critically ill patients → **FDA Breakthrough Therapy Designation**, launching in 2025—**A new leader

$Flux Power (FLUX.US)$